Gender Equality and Diversity at HT – Symposium
The first symposium on “Gender Equality and Diversity at HT” took place today at the Human Technopole Auditorium. The aim of the event was to discuss why there are differences in the career outcomes of men and women and how we can act to promote equality and inclusion at HT. During the event we heard from Gerlind Wallon, Deputy Director of the European Molecular Biology Organisation (EMBO) and Saher Ahmed, Head of Diversity Equality and Inclusion at the Sanger Institute. The aim is to start a conversation on how both our personal actions and institutional policies can best promote equality and inclusion at Human Technopole.
PROGRAMME
14.00 – 14.05: Welcome to HT. GIANMARIO VERONA (President, HT)
14.05-14.15: Introduction. NICOLE SORANZO (Head of Genomics Research Centre, Population & Medical Genomics, HT)
14.15-14.45: «Gender in Academia». GERLIND WALLON (Deputy Director, EMBO)
14.45-15-15: «Our journey in Equality, Diversity and Inclusion». SAHER AHMED (Head of Equality, Diversity and Inclusion, Sanger Institute )
15.15-15.45: Q&A session. NICOLE SORANZO (Head of Genomics Research Centre, Population & Medical Genomics, HT)
15.45-16.15: COFFEE BREAK
16.15-16.30: «HT Gender Equality Plan and Gender Equality Team at HT». ALESSANDRA POGGIANI (Director of Administration, HT)
16.30-16.50: Ideas for the future. Chaired by NICOLE SORANZO, GERLIND WALLON , SAHER AHMED, ALESSANDRA POGGIANI
16.50-17.00: Closing Remarks
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.